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Background: Multimodal analgesia following total hip arthroplasty has been shown to improve patient satisfaction,
participation with physical therapy, and allow early return to self care. Liposomal bupivacaine is a formulation of
local anesthetic which has the potential to provide anesthesia for up to 72 hours following administration. The
purpose of this study was to compare the effectiveness of liposomal bupivacaine with bupivacaine following total
hip arthroplasty.
Methods: A retrospective chart review was performed on 28 patients undergoing total hip arthroplasty or hip
resurfacing who received intraoperative administration of liposomal bupivacaine. A control group of 30 patients
who had previously undergone total hip arthroplasty or hip resurfacing and had received intraoperative
administration of bupivacaine also underwent a chart review. Length of stay, post-operative opioid use, and pain
scores were compared for both groups.
Results: The average length of stay in the study group was 1.93 days and the control group length of stay was
2.47 days (p ≤ 0.05). Morphine equivalent use was less in the study group during the first 24 hours compared to the
control group (p ≤0.05). During the second and third 24 hours the morphine equivalent use difference was not
statistically significant. Visual analogue scores were not significantly different between groups at any time point.
Conclusion: Liposomal bupivacaine administration during total hip arthroplasty appears to decrease the need for
opioid use post operatively and decrease length of stay. The results of this study justify the need for a well-designed
randomized controlled trial utilizing liposomal bupivacaine as part of multimodal analgesia during THA.Background
Multimodal analgesia following total hip arthroplasty
(THA) has been shown to improve patient satisfaction,
participation with physical therapy, and allow early re-
turn to self care [1]. Opioid related side effects are dose
dependent, and efforts to minimize opioid consumption
through peripheral nerve blockade, epidural anesthesia,
local anesthetics, and non-opioid medications have been
effective [2-5]. Ideally, following THA, analgesic related* Correspondence: DrDomb@americanhipinstitute.org
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unless otherwise stated.side effects are minimized to allow early mobilization
and recovery [6].
Epidural and peripheral nerve blockade have been
used as methods to decrease post operative opiate con-
sumption following THA [2,7]. Epidural anesthesia is an
effective method of pain control. However, muscular
blockade can reduce a patient’s ability to participate in
physical therapy, and the need for venous thrombo-
embolism prophylaxis puts patients at risk for epidural
hematoma. Lumbar plexus and femoral nerve blocks
have been used as a single shot and continuous infusion
for postoperative analgesia following THA [2,8]. Con-
tinuous lumbar plexus blocks have been shown to be ef-
fective in reducing pain scores, opioid consumption, and
side effects [2]. However, trained personal, operating
room delays, and post-operative motor weakness haveLtd. This is an Open Access article distributed under the terms of the Creative
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use of a catheter and potential need for monitoring are
also barriers to outpatient THA.
The use of local anesthetics and local infiltration anal-
gesia has been used following THA with mixed results
[4,5,9,10]. A recent level one study compared local infil-
tration analgesia to a placebo as part of multimodal an-
algesia following THA and found no benefit in the
study group [9]. This study was also unable to detect a
difference between patients with continuous postopera-
tive intra-articular infusion of ropivicaine compared to
patients not receiving an infusion. This contrasts with
previous randomized controlled trials investigating infil-
tration analgesia in the setting of THA, which have
shown a benefit compared to a control group, and when
compared to patients receiving epidural analgesia [4,5].
Liposomal bupivacaine is a formulation of local anesthetic
approved by the FDA in October 2011 for single-dose in-
filtration in the surgical site for postsurgical analgesia.
Bupivicaine is released from multivesicular liposomes over
a period of time, which may result in local anesthetic ac-
tion for up to 72 hours. This method of delivery has to the
potential reduce opioid consumption without the need for
a nerve block or catheter placement. To our knowledge,
this method of local anesthetic delivery has not been in-
vestigated during THA. The purpose of this study was to
compare the effectiveness of liposomal bupivacaine with
standard bupivacaine following total hip arthroplasty. We
hypothesized that narcotic use and length of stay would be
decreased by the use of liposomal bupivacaine. Pain scores
have historically been relatively low using narcotic pain
control, and therefore were expected to remain unchanged
while the use of narcotics was decreased.
Methods
Study design
A retrospective chart review was performed on 28 patients
undergoing total hip arthroplasty or hip resurfacing who
received intraoperative administration of liposomal bupi-
vacaine. A control group of 30 patients who had previ-
ously undergone total hip arthroplasty or hip resurfacing
and had received intraoperative administration of bupiva-
caine also underwent a chart review. The study period was
from November 2012 to May 2013. Patients received a
preoperative analgesic regimen, which typically included
1000 mg of oral acetaminophen, 400 mg of oral celecoxib,
75 mg of oral pregabalin, and 10 mg of oral extended re-
lease oxycodone. Exclusion criteria were revision surgery,
previous opioid dependence, and surgical approaches
other than posterior.
Surgical technique
All surgical procedures were performed by the senior
surgeon (BGD). All patients had total hip arthroplasty orhip resurfacing through a posterior approach. During
wound closure all patients underwent injection of lipo-
somal bupivacaine or bupivacaine throughout the hip
capsule, external rotators, gluteus medius, gluteus mini-
mus, gluteus maximus, tensor fascia lata, vastus lateralis,
and subcutaneous tissues. Intra-operative analgesia was
used by anesthesiologists and consisted of fentanyl or
hydromorphone as needed for pain control.
Bupivicaine administration
All patients received an intra-operative local anesthetic
injection. The study group received 20 mL (266 mg) of
liposomal bupivacaine mixed with 40 mL of 0.25% bupi-
vacaine with epinephrine. The control group received
60 mL of 0.25% bupivacaine with epinephrine. Care was
taken to avoid the sciatic and femoral nerves during ad-
ministration. Both liposomal bupivacaine and bupiva-
caine are considered part of the standard of care in hip
arthroplasty.
Postoperative care
All patients were allowed to discharge from the hospital
when they met discharge criteria. Discharge criteria in-
cluded adequate pain control utilizing an oral regimen,
tolerating oral intake, and ability to self care. Nurses ob-
served patients postoperatively and administered opioid
medication as needed for comfort. Patients and nurses
utilized ketorolac, hydrocodone, acetaminophen, codeine,
fentanyl, hydromophone, extended release oxycodone, and
oxycodone for pain control. Physical therapy was initi-
ated within 24 hours following surgery to assist with
ambulation.
Outcome measures
Following surgery patients were discharged when they
met criteria. Length of stay was recorded in days for all
patients. Post operative opioid consumption was re-
corded for all patients in the hospital. Opioids adminis-
tered were converted to morphine equivalents for all
patients. Opioid use was tabulated as morphine equiva-
lents in the first 24 hours, second 24 hours, and third
24 hours following surgery. Opioid use after 72 hours
was not collected. Patients reported their pain on a vis-
ual analog scale (VAS) from 0 to 10, where 0 was con-
sidered to be no pain at all and 10 was considered to be
the worst possible pain. Average pain scores were tabu-
lated for the first 24 hours, second 24 hours, and third
24 hours following surgery. Readmissions related to pain
control were recorded.
Statistics
A chi-squared analysis was used to compare categorical
data between groups such as gender distribution. The
two-tailed, independent t-test was used to assess length
Table 2 Study measurements between the study and
control group for length of stay, pain measurements for
the first 72 hours, and morphine equivalents for the first
72 hours
Study Control t-test
Average Count Average Count
Length of stay 1.93 27 2.47 30 0.050
Morphine
First 24 hours 24.00 27 53.35 30 0.000
Second 24 hours 41.08 13 64.94 25 0.102
Third 24 hours 39.58 6 48.77 13 0.651
Pain scores
First 24 hours 2.81 27 2.82 30 0.968
Second 24 hours 3.27 12 3.29 25 0.964
Third 24 hours 2.20 7 2.61 13 0.557
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A-priori sample size was calculated for a two-tailed hy-
pothesis utilizing a mean difference in morphine equiva-
lent use of 7 mg with a standard deviation of 8 mg [11]. A
sample size of 34 patients would be needed for a power
(beta) of 0.8 and probability level (alpha) of 0.05. A p-value
of <0.05 was considered significant. Statistical analysis
was done using Microsoft Office Excel 2007 (Redmond,
Washington, USA).
Ethical approval
Institutional Review Board approval from Adventist
Hinsdale Hospital, affiliated with Advocate Healthcare,
was obtained and patient informed consent was obtained
as well. STROBE guidelines for observational studies
were adhered to for this study,
Results
Patient demographics are displayed in Table 1. No sig-
nificant differences between groups were noted for age
or gender. The study group included 24 THA patients
and 3 hip resurfacing patients, and the control group in-
cluded 20 THA patients and 10 hip resurfacing patients.
The control group did include more hip resurfacing pa-
tients than the study group (p < 0.05). One patient from
the study group was excluded due to previous opioid tol-
erance, leaving 27 patients for evaluation.
The average length of stay in the study group was
1.93 days and the control group length of stay was
2.47 days (p ≤ 0.05) (Table 2).
The study group and control group morphine equiva-
lent use in the first, second, and third 24 hour intervals
are displayed in Table 2. Morphine equivalent use was
less in the study group during the first 24 hours com-
pared to the control group (p ≤ 0.05) (Figure 1). During
the second and third 24 hours the morphine equivalent
use difference was not statistically significant. Morphine












Total 27discharge. In the study group 13 patients were available
for the second 24 hours, and 6 were available for the
third 24 hours. In the control group 25 patients were
available for the second 24 hours, and 13 were available
for the third 24 hours.
The study group and control group average VAS during
the first, second, and third 24 hour intervals are displayed
in Table 2. VAS was not significantly different between
groups at any time point (Figure 2). VAS could not be cal-
culated following hospital discharge. In the study group 12
patients were available for the second 24 hours, and 7
were available for the third 24 hours. In the control group
25 patients were available for the second 24 hours, and 13
were available for the third 24 hours.
There were no readmissions secondary to pain control
in either group. The one patient excluded from the
study group for history of opioid use was readmitted for
pain control. This patient required more morphine
equivalents during the first 24 hours (1,150 mg) than











Figure 1 Morphine equivalent use in milligrams during the first 24 hour period, the second 24 hour period and third 24 hour period
following surgery for the study and control groups.
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Multimodal analgesia following total hip arthroplasty
(THA) has the potential to improve pain control and limit
opioid related side effects. Recent efforts to use local anes-
thetics in THA have been limited to peripheral nerve
blockade and local infiltration analgesia [1,5,9,10,12]. Lipo-
somal bupivacaine is a novel method of local anesthetic de-
livery, and obviates the need for nerve blocks and catheter
placement. In the present study, patients treated with lipo-
somal bupivacaine demonstrated decreased length of stay
and decreased morphine equivalent use during the first
24 hours following total hip arthroplasty, when compared
to a control group treated with standard bupivicaine.
Given the recent approval of liposomal bupivacaine,
there are no similar studies on the use of this delivery
method for THA. The results of this pilot study will be
used to design a randomized controlled trial. Bramlett
et al. investigated the use of a liposomal release bupiva-
caine during total knee arthroplasty and noted improvedFigure 2 VAS average during the first 24 hour period, the second 24
study and control groups.analgesia compared to patients treated with bupivacaine
infiltration alone [13]. The results of the current study
mirror the decreased morphine equivalent use in pa-
tients treated with liposomal bupivacaine, although we
did not detect a significant difference in pain scores be-
tween groups.
There have been recent reports in the general surgery
literature examining the effect of liposomal bupivacaine
for post operative analgesia [14-16]. To our knowledge
there is one randomized controlled trial involving liposo-
mal bupivacaine in the literature [17]. This study involved
patients undergoing hemorrhoidectomy and compared li-
posomal bupivacaine to placebo. This trial demonstrated
decreased pain, opioid requirements, delayed time to first
opioid use, and improved patient satisfaction in the study
group. In this study the reduction in pain lasted 72 hours.
The current study differs from this randomized trial in
that the control group in the current study received stand-
ard bupivacaine, not a placebo.hour period and third 24 hour period following surgery for the
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liposomal bupivacaine for THA in the literature. It com-
pares a similar group of patients, all of which underwent
a posterior approach for hip arthroplasty by a single sur-
geon. It also addresses the clinically relevant question –
whether liposomal bupivacaine yields improved results
compared to standard bupivacaine; rather than comparing
liposomal bupivacaine to a placebo or intravenous patient
controlled analgesia. Finally, statistically significant differ-
ences were found in length of stay and postoperative nar-
cotic use.
This study has many limitations. The retrospective na-
ture of this study precludes the ability to standardize
preoperative and postoperative multimodal analgesia, se-
lect patients, and standardize perioperative care, which
may have led to undetectable bias between groups. How-
ever, the groups were homogeneous in that they con-
sisted of only posterior approach hip arthroplasties, all
performed by the same surgeon, thus removing surgeon
technique and surgical approach as confounding vari-
ables. Second, there were more hip resurfacings in the
control group. Third, the average age of arthroplasty pa-
tients in this study for both groups is 55 years; this rep-
resents a slightly younger patient cohort than many
arthroplasty practices. Whether these results can be ex-
trapolated to an older patient population is unknown.
Conclusion
Liposomal bupivacaine administration during total hip
arthroplasty appears to decrease the need for opioid use
post operatively and decrease length of stay requirements.
The results of this study justify the need for a well-
designed randomized controlled trial utilizing liposomal
bupivacaine as part of multimodal analgesia during THA.
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